Page 60 - GPD-3-1

Gene & Protein in Disease Prognostic potential of LMNB2 in LPS

CD80 and CD86 costimulatory molecules regulate crescentic 56. Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment
glomerulonephritis by different mechanisms. Kidney Int. and characterization of NCC-PLPS1-C1, a novel patient-
2005;68(2):584-594. derived cell line of pleomorphic liposarcoma. Human Cell.
2021;34(2):688-697.
doi: 10.1111/j.1523-1755.2005.00436.x
doi: 10.1007/s13577-020-00457-0
46. Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale
behind targeting the ICOS-ICOS ligand costimulatory pathway 57. Zhou MY, Bui NQ, Charville GW, Ganjoo KN, Pan M.
in cancer immunotherapy. ESMO Open. 2020;5(1):e000544. Treatment of de-differentiated liposarcoma in the era of
immunotherapy. Int J Mol Sci. 2023;24(11):9571.
doi: 10.1136/esmoopen-2019-000544
doi: 10.3390/ijms24119571
47. Chen L, Flies DB. Molecular mechanisms of T cell
co-stimulation and co-inhibition. Nat Rev Immunol. 58. Qin H, Lu Y, Du L, et al. Pan-cancer analysis identifies
2013;13(4):227-242. LMNB1 as a target to redress Th1/Th2 imbalance and
enhance PARP inhibitor response in human cancers. Cancer
doi: 10.1038/nri3405
Cell Int. 2022;22(1):101.
48. Tian J, Zhang B, Rui K, Wang S. The role of GITR/GITRL doi: 10.1186/s12935-022-02467-4
interaction in autoimmune diseases. Front Immunol.
2020;11:588682. 59. Endo-Munoz L, Dahler A, Teakle N, et al. E2F7 can regulate
proliferation, differentiation, and apoptotic responses in
doi: 10.3389/fimmu.2020.588682 human keratinocytes: Implications for cutaneous squamous
49. Song X, Zhou Z, Li H, et al. Pharmacologic suppression cell carcinoma formation. Cancer Res. 2009;69(5):1800-1808.
of B7-H4 glycosylation restores antitumor immunity doi: 10.1158/0008-5472.Can-08-2725
in immune-cold breast cancers. Cancer Discov.
2020;10(12):1872-1893. 60. Zong S, Liu X, Zhou N, Yue Y. E2F7, EREG, miR-451a
and miR-106b-5p are associated with the cervical cancer
doi: 10.1158/2159-8290.Cd-20-0402 development. Arch Gynecol Obstet. 2019;299(4):1089-1098.
50. Bock S, Hoffmann DG, Jiang Y, Chen H, Il’yasova D. doi: 10.1007/s00404-018-5007-y
Increasing incidence of liposarcoma: A population-based
study of national surveillance databases, 2001-2016. Int J 61. Kim LK, Park SA, Eoh KJ, Heo TH, Kim YT, Kim HJ. E2F8
Environ Res Public Health. 2020;17(8):2710. regulates the proliferation and invasion through epithelial-
mesenchymal transition in cervical cancer. Int J Biol Sci.
doi: 10.3390/ijerph17082710 2020;16(2):320-329.
51. Bartlett EK, Curtin CE, Seier K, et al. Histologic subtype doi: 10.7150/ijbs.37686
defines the risk and kinetics of recurrence and death
for primary extremity/truncal liposarcoma. Ann Surg. 62. Iino K, Mitobe Y, Ikeda K, et al. RNA-binding protein NONO
2021;273(6):1189-1196. promotes breast cancer proliferation by post-transcriptional
regulation of SKP2 and E2F8. Cancer Sci. 2020;111(1):148-159.
doi: 10.1097/sla.0000000000003453
doi: 10.1111/cas.14240
52. Zheng K, Yu XC, Xu M, Yang Y. Surgical outcomes and
prognostic factors of myxoid liposarcoma in extremities: 63. Yang R, Wang M, Zhang G, et al. E2F7-EZH2 axis regulates
A retrospective study. Orthop Surg. 2019;11(6):1020-1028. PTEN/AKT/mTOR signalling and glioblastoma progression.
Br J Cancer. 2020;123(9):1445-1455.
doi: 10.1111/os.12566
doi: 10.1038/s41416-020-01032-y
53. Bill KL, Casadei L, Prudner BC, Iwenofu H, Strohecker AM,
Pollock RE. Liposarcoma: Molecular targets and therapeutic 64. Wajant H. Therapeutic targeting of CD70 and CD27. Expert
implications. Cell Mol Life Sci. 2016;73(19):3711-3718. Opin Ther Targets. 2016;20(8):959-973.
doi: 10.1007/s00018-016-2266-2 doi: 10.1517/14728222.2016.1158812
54. Thway K. Well-differentiated liposarcoma and 65. Chen DS, Mellman I. Oncology meets immunology: The
dedifferentiated liposarcoma: An updated review. Semin cancer-immunity cycle. Immunity. 2013;39(1):1-10.
Diagn Pathol. 2019;36(2):112-121. doi: 10.1016/j.immuni.2013.07.012
doi: 10.1053/j.semdp.2019.02.006 66. Rotte A. Combination of CTLA-4 and PD-1 blockers for
treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.
55. Schöffski P. Established and experimental systemic
treatment options for advanced liposarcoma. Oncol Res doi: 10.1186/s13046-019-1259-z
Treat. 2022;45(9):525-543.
67. Shimi T, Pfleghaar K, Kojima S, et al. The A- and B-type
doi: 10.1159/000524939 nuclear lamin networks: Microdomains involved in

Volume 3 Issue 1 (2024) 14 https://doi.org/10.36922/gpd.2607